Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression
Sponsor: Dartmouth-Hitchcock Medical Center
This PHASE3 trial investigates Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia and is currently ongoing. Dartmouth-Hitchcock Medical Center leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 8 earlier versions
-
Feb 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Jun 2021 — Feb 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Apr 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE3
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .